A61K 51/041
Heterocyclic compounds
Official title: {Heterocyclic compounds}
A61K51/041 (Heterocyclic compounds) appears on 946 US grants and 1,532 published applications in this corpus.
Search patents in A61K- Granted patents
- 946
- Published applications
- 1,532
- Assignees
- 619
- Inventors
- 2,964
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 1 | 0 |
| 1977 | 0 | 0 |
| 1978 | 0 | 0 |
| 1979 | 0 | 0 |
| 1980 | 1 | 0 |
| 1981 | 3 | 0 |
| 1982 | 1 | 0 |
| 1983 | 0 | 0 |
| 1984 | 4 | 0 |
| 1985 | 0 | 0 |
| 1986 | 2 | 0 |
| 1987 | 0 | 0 |
| 1988 | 3 | 0 |
| 1989 | 6 | 0 |
| 1990 | 6 | 0 |
| 1991 | 4 | 0 |
| 1992 | 6 | 0 |
| 1993 | 4 | 0 |
| 1994 | 9 | 0 |
| 1995 | 7 | 0 |
| 1996 | 7 | 0 |
| 1997 | 6 | 0 |
| 1998 | 10 | 0 |
| 1999 | 14 | 0 |
| 2000 | 14 | 0 |
| 2001 | 11 | 5 |
| 2002 | 17 | 16 |
| 2003 | 17 | 31 |
| 2004 | 11 | 28 |
| 2005 | 19 | 29 |
| 2006 | 11 | 27 |
| 2007 | 10 | 25 |
| 2008 | 22 | 34 |
| 2009 | 11 | 50 |
| 2010 | 18 | 61 |
| 2011 | 19 | 55 |
| 2012 | 35 | 55 |
| 2013 | 45 | 74 |
| 2014 | 46 | 94 |
| 2015 | 52 | 78 |
| 2016 | 37 | 82 |
| 2017 | 58 | 65 |
| 2018 | 58 | 75 |
| 2019 | 55 | 75 |
| 2020 | 52 | 82 |
| 2021 | 54 | 80 |
| 2022 | 31 | 92 |
| 2023 | 33 | 62 |
| 2024 | 48 | 94 |
| 2025 | 25 | 92 |
| 2026 | 43 | 71 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Near-infrared dyes and conjugates for targeting tumors6 Oct 2026US 12,752,023 B2Lahjavida, LLC
- Urokinase plasminogen activator receptor-targeted radiopharmaceutical22 Sep 2026US 12,741,039 B2Monopar Therapeutics Inc.
- Macrocyclic complexes of alpha-emitting radionuclides and their use in targeted radiotherapy of cancer22 Sep 2026US 12,741,964 B2Cornell University
- Radioligands for pretargeted PET imaging and methods of their therapeutic use15 Sep 2026US 12,734,258 B2Memorial Sloan Kettering Cancer Center
- Radiolabelled compound18 Aug 2026US 12,709,601 B2Oxford University Innovation Limited
- Compounds useful for in vivo imaging of protein oxidation and/or cancer treatment1 Oct 2026US 2026/0295098 A1Wake Forest University Health Sciences
- Imaging methods and agents for grading and staging and subsequent treatment of prostate cancer in a patient24 Sep 2026US 2026/0284233 A1
- Isoindolinone compounds and imaging agents for imaging huntingtin protein24 Sep 2026US 2026/0284234 A1CHDI Foundation, Inc.
- Radiolabeled fapi complex, and preparation method therefor and use thereof24 Sep 2026US 2026/0284237 A1Beijing Normal University
- Radiolabeled Fibroblast Activation Protein Inhibitors and Methods of Making Same17 Sep 2026US 2026/0273110 A1The Regents of the University of Michigan
Most cited
By later US patents
- Glycine receptor antagonists and the use thereof159US 5,514,680 AState of Oregon, acting by and through the Oregon State Board of Higher Education, acting for and on behalf of the Oregon Health Sciences University · 1996
- Vitamin-targeted imaging agents155US 7,128,893 B2Endocyte, Inc. · 2006
- System for targeted delivery of therapeutic agents127US 8,709,483 B2Massachusetts Institute of Technology · 2014
- Composition and method for tumor imaging123US 5,688,488 APurdue Research Foundation · 1997
- Radiolabeled farnesyl-protein transferase inhibitors111US 6,060,038 AMerck & Co., Inc. · 2000